NEW YORK — Immune profiling firm Immunai said on Thursday that it has raised $60 million in a Series A funding round.
The Tel Aviv- and New York City-based company said it plans to use the funds to expand its Annotated Multi-omic Immune Cell Atlas (AMICA) and to extend its functional genomics capabilities to reprogram immune cells and validate drug targets.
The round was led by Schusterman Family Investments, Duquesne Family Office, Catalio Capital Management, and Dexcel Pharma with existing investors Viola Ventures and TLV Partners also participating.
"Since Immunai’s founding in 2018, we have been mapping the immune system through observational genomics, using multi-omic single-cell technologies and machine learning to better understand how the immune system operates," Noam Solomon, Immunai's cofounder and CEO, said in a statement. "Our expansion into functional genomics will help our partners tackle their most pressing questions in therapy development and will ultimately improve the lives of many patients."
“It’s increasingly clear that the immune system is even more complex than we imagined, and advancing our understanding requires combining new techniques with big data approaches,” said Kenan Turnacioglu, general partner at Catalio Capital Management and a member of Immunai's board of directors. "This intersection is reflected in Immunai's founding team and leadership, and I’m excited to be working with the company on this next phase of growth, as they bring together the brightest minds in the fields of single-cell genomics, immunology, machine learning, and data engineering to take on this task."
Immunai has now raised more than $80 million since its launch.